3D MR Spectroscopic Imaging of 2-Hydroxyglutarate in patients with mutant IDH1 glioma
نویسندگان
چکیده
Ovidiu Cristian Andronesi, Franziska Loebel, Wolfgang Bogner, Malgorzata Marjanska, Elizabeth Gerstner, Andrew Chi, Tracy T. Batchelor, Daniel P. Cahill, and Bruce R. Rosen Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, United States, MR Center of Excellence, Department of Radiology, Medical University Vienna, Vienna, Vienna, Austria, Center for Magnetic Resonance Research, University of Minnesota, MN, United States, Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
منابع مشابه
Tumor and Stem Cell Biology IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma
Many patients with glioma harbor specificmutations in the isocitrate dehydrogenase gene IDH1 that associate with a relatively better prognosis. IDH1-mutated tumors produce the oncometabolite 2-hydroxyglutarate. Because IDH1 also regulates several pathways leading to lipid synthesis, we hypothesized that IDH1-mutant tumors have an altered phospholipid metabolite profile that would impinge on tum...
متن کاملIDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.
Many patients with glioma harbor specific mutations in the isocitrate dehydrogenase gene IDH1 that associate with a relatively better prognosis. IDH1-mutated tumors produce the oncometabolite 2-hydroxyglutarate. Because IDH1 also regulates several pathways leading to lipid synthesis, we hypothesized that IDH1-mutant tumors have an altered phospholipid metabolite profile that would impinge on tu...
متن کاملD-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma
BACKGROUND IDH mutations frequently occur in diffuse gliomas and result in a neo-enzymatic activity that results in reduction of α-ketoglutarate to D-2-hydroxyglutarate. In gliomas, the frequency of IDH1 mutations in codon 132 increases in the order R132L-R132S-R132G-R132C-R132H with R132H constituting more than 90% of all IDH1 mutations. RESULTS We determined the levels of D-2-hydroxyglutara...
متن کاملDetection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
Mutations in the gene isocitrate dehydrogenase 1 (IDH1) are present in up to 86% of grade II and III gliomas and secondary glioblastoma. Arginine 132 (R132) mutations in the enzyme IDH1 result in excess production of the metabolite 2-hydroxyglutarate (2HG), which could be used as a biomarker for this subset of gliomas. Here, we use optimized in vivo spectral-editing and two-dimensional (2D) cor...
متن کاملTreatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
PURPOSE Measurements of objective response rates are critical to evaluate new glioma therapies. The hallmark metabolic alteration in gliomas with mutant isocitrate dehydrogenase (IDH) is the overproduction of oncometabolite 2-hydroxyglutarate (2HG), which plays a key role in malignant transformation. 2HG represents an ideal biomarker to probe treatment response in IDH-mutant glioma patients, an...
متن کامل